Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01058005 |
Recruitment Status :
Terminated
(Due to significantly slower than expected enrollment, the Sponsor decided to terminate the study.)
First Posted : January 28, 2010
Results First Posted : August 13, 2014
Last Update Posted : September 3, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Relapsing Remitting Multiple Sclerosis | Drug: BG00002 (natalizumab) Drug: interferon beta-1a Drug: glatiramer acetate | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 84 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Official Title: | A Multicenter, Randomized, Open-Label, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon Beta-1a) to Natalizumab in Subjects With Relapsing Remitting Multiple Sclerosis |
Study Start Date : | March 2010 |
Actual Primary Completion Date : | April 2012 |
Actual Study Completion Date : | April 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: Natalizumab |
Drug: BG00002 (natalizumab)
300 mg intravenous injection every 4 weeks
Other Name: Tysabri |
Active Comparator: Interferon Beta-1a |
Drug: interferon beta-1a
44 mcg subcutaneous injection 3 times per week
Other Name: Rebif |
Active Comparator: Glatiramer Acetate |
Drug: glatiramer acetate
20 mg subcutaneous injection once daily
Other Name: Copaxone |
- Incidence of Treatment-emergent Serious Adverse Events (SAEs) [ Time Frame: up to 108 Weeks ]An SAE was defined as any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the subject at immediate risk of death (a life-threatening event; however, this does not include an event that, had it occurred in a more severe form, might have caused death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or results in a congenital anomaly/birth defect. An SAE may also have been any other medically important event that, in the opinion of the Investigator, may jeopardize the subject or may require intervention to prevent one of the other outcomes listed in the definition above. See Adverse Events section below for further details.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Have a diagnosis of relapsing remitting multiple sclerosis (MS) as defined by the revised McDonald Committee criteria (Polman 2005).
- Must have been treated with a stable regimen of either glatiramer acetate (20 mg per day subcutaneous) or interferon beta-1a (44 mcg 3 times per week subcutaneous) as their principal first therapy for MS for 6 to 18 months prior to randomization. (Note: prior treatment with another MS therapy of ≤ 30 days total duration is not exclusionary [e.g. titration to 44 mcg is allowed]).
-
Have had disease activity within 12 months prior to screening while on therapy; disease activity must be observed after a minimum of 6 months on therapy. Qualifying disease activity is defined as:
- One or more clinical relapses OR
- Two or more new MRI lesions (gadolinium [Gd+] and/or T2 hyperintense) For inclusion purposes: (a) a relapse is defined as neurologic signs and/or symptoms documented in the medical record by a neurologist and of sufficient duration to be determined by the Investigator or the Treating Physician as consistent with an MS relapse or (b) MRI activity must be verified by the central reader center.
- Be naïve to natalizumab.
- Have a documented Expanded Disability Status Scale (EDSS) score between 0.0 and 5.5, inclusive.
Key Exclusion Criteria:
- Have a diagnosis of primary progressive, secondary progressive, or progressive relapsing MS (as defined by Lublin and Reingold, 1996). These conditions require the presence of continuous clinical disease worsening over a period of at least 3 months. Patients with these conditions may also have superimposed relapses, but are distinguished from relapsing-remitting patients by the lack of clinically stable periods or clinical improvement.
- Have known intolerance, contraindication to, or history of non-compliance with, the use of glatiramer acetate or interferon beta-1a.
- Have had an MS exacerbation (relapse) within 30 days prior to randomization AND/OR the patient has not stabilized from a previous relapse, in the opinion of the Investigator, prior to randomization.
- The patient is considered by the Investigator to be immunocompromised based on medical history, physical examination, laboratory testing, or due to prior immunosuppressive or immunomodulating treatment.
- Subjects for whom MRI is contraindicated, i.e., have pacemakers or other contraindicated implanted metal devices, have suffered or are at risk for side effects from gadolinium (Gd), or have claustrophobia that cannot be medically managed.
- History of any clinically significant (as determined by the Investigator) cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease that would preclude participation in a clinical trial.
- History of malignant disease, including solid tumors and hematologic malignancies (with the exception of basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured).
- Known history of human immunodeficiency virus (HIV).
- Positive test result for hepatitis C virus (test for hepatitis C virus antibody [HCVAb]) or hepatitis B virus (test for hepatitis B surface antigen [HBsAg] and/or hepatitis B core antibody [HBcAb]).
- History of transplantation or any anti-rejection therapy.
- History of progressive multifocal leukoencephalopathy (PML).
NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01058005
United States, Alabama | |
Research Site | |
Cullman, Alabama, United States | |
United States, Arizona | |
Research Site | |
Phoenix, Arizona, United States | |
United States, Colorado | |
Research Site | |
Fort Collins, Colorado, United States | |
United States, Florida | |
Research Site | |
Maitland, Florida, United States | |
Research Site | |
Saint Petersburg, Florida, United States | |
Research Site | |
Tampa, Florida, United States | |
United States, Georgia | |
Research Site | |
Atlanta, Georgia, United States | |
United States, Kentucky | |
Research Site | |
Lexington, Kentucky, United States | |
United States, Louisiana | |
Research Site | |
New Orleans, Louisiana, United States | |
United States, Michigan | |
Research Site | |
Detroit, Michigan, United States | |
United States, New York | |
Research Site | |
Patchogue, New York, United States | |
United States, North Carolina | |
Research Site | |
Charlotte, North Carolina, United States | |
United States, Ohio | |
Research Site | |
Akron, Ohio, United States | |
United States, Tennessee | |
Research Site | |
Franklin, Tennessee, United States | |
Research Site | |
Knoxville, Tennessee, United States | |
United States, Texas | |
Research Site | |
Round Rock, Texas, United States | |
United States, Virginia | |
Research Site | |
Norfolk, Virginia, United States | |
United States, Washington | |
Research Site | |
Kirkland, Washington, United States | |
United States, West Virginia | |
Research Site | |
Morgantown, West Virginia, United States | |
Australia, Victoria | |
Research Site | |
Fitzroy, Victoria, Australia | |
Canada, Quebec | |
Research Site | |
Gatineau, Quebec, Canada | |
Czech Republic | |
Research Site | |
Pardubice, Czech Republic | |
Finland | |
Research Site | |
Tampere, Finland | |
France | |
Research Site | |
Strasbourg, Bas-Rhin, France | |
Hungary | |
Research Site | |
Esztergom, Komárom-Esztergom, Hungary | |
Research Site | |
Budapest, Hungary | |
Research Site | |
Nyiregyhaza, Hungary | |
Italy | |
Research Site | |
Catania, Italy | |
Research Site | |
Napoli, Italy | |
Research Site | |
Rome, Italy | |
Latvia | |
Research Site | |
Riga, Latvia | |
Poland | |
Research Site | |
Lódz, Lodzkie, Poland | |
Research Site | |
Bialystok, Podlaskie, Poland | |
Research Site | |
Gdansk, Pomorskie, Poland | |
Slovenia | |
Research Site | |
Ljubljana, Slovenia | |
Spain | |
Research Site | |
Alicante, Spain | |
Research Site | |
Barcelona, Spain | |
Research Site | |
Girona, Spain | |
Research Site | |
Madrid, Spain | |
Research Site | |
Santa Cruz de Tenerife, Spain | |
Research Site | |
Sevilla, Spain | |
Sweden | |
Research Site | |
Molndal, Sweden |
Study Director: | Medical Director | Biogen |
Responsible Party: | Biogen |
ClinicalTrials.gov Identifier: | NCT01058005 |
Other Study ID Numbers: |
101MS325 |
First Posted: | January 28, 2010 Key Record Dates |
Results First Posted: | August 13, 2014 |
Last Update Posted: | September 3, 2014 |
Last Verified: | August 2014 |
MS |
Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting Sclerosis Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases Interferons Interferon-beta |
Interferon beta-1a Glatiramer Acetate Natalizumab (T,G)-A-L Antineoplastic Agents Antiviral Agents Anti-Infective Agents Immunologic Factors Physiological Effects of Drugs Adjuvants, Immunologic Immunosuppressive Agents Antirheumatic Agents |